PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D change of 88.49% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
34.89%
G&A change of 34.89% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses change of 77.92% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
59.22%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.78%. Jim Chanos would check for waste.
59.22%
Total costs growth exceeding 1.5x Biotechnology median of 1.07%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
77.92%
D&A change of 77.92% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-37.27%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-272.88%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-313.33%
Diluted EPS decline while Biotechnology median is 1.71%. Seth Klarman would investigate causes.
10.47%
Share count reduction below 50% of Biotechnology median of 0.28%. Jim Chanos would check for issues.
-20.54%
Diluted share reduction while Biotechnology median is 0.38%. Seth Klarman would investigate strategy.